HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced it has entered into a Letter of Intent to acquire the assets of a Central American Immunotherapy Company. The acquisition will include a family of immunotherapy products that have been approved for the treatment of patients as an alternative to or as an adjunct therapy before, during and after traditional cancer treatments. HST anticipates completing the pending acquisition of the company at the conclusion of the due diligence period.
